cognition/cognitive therapyFamily PracticeNeurologyInternal MedicinePathologyGeriatricsHealth TechnologyGeneticsMental HealthCognitive Therapy
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Jan. 25, 2018 (HealthDay News) -- A multidomain lifestyle intervention seems to be beneficial for cognition in older at-risk individuals, even among apolipoprotein E (APOE) ε4 carriers, according to a study published online Jan. 22 in JAMA Neurology.
Alina Solomon, M.D., Ph.D., from the University of Eastern Finland in Kuopio, and colleagues analyzed data from the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, in which at-risk older individuals (aged 60 to 77 years) were randomized to a multidomain intervention group (diet, exercise, cognitive training, and vascular risk management) or a control group (general healthy advice). A total of 1,109 participants were included in the analysis: 362 APOE ε4 allele carriers and 747 noncarriers.
The researchers found that for the annual neuropsychological test battery total score change, the difference between the intervention and control groups was 0.037 (95 percent confidence interval, 0.001 to 0.073) among carriers and 0.014 (95 percent confidence interval, −0.011 to 0.039) among noncarriers. There was no significant difference in the intervention effect between carriers and noncarriers (0.023; 95 percent confidence interval, −0.021 to 0.067).
"Healthy lifestyle changes may be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia," the authors write. "Whether such benefits are more pronounced in APOE ε4 carriers compared with noncarriers should be further investigated."
The study was funded in part by the Novo Nordisk Foundation.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 28, 2022
Read this Next
Other Trending Articles